This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Analysts' Actions: C.R. Bard, Gap, GNC, Medtronic, Tyson Foods

NEW YORK (TheStreet) -- RATINGS CHANGES

Ambit Biosciences (AMBI) was initiated with a sell rating at TheStreet Ratings.

Gap (GPS - Get Report) was upgraded at Canaccord Genuity to buy from hold. Twelve-month price target is $51. Company can continue to expand margins, Canaccord Genuity said.

C.R. Bard (BCR - Get Report) was downgraded at Barclays to equal weight from overweight. Pressure on company due to its exposure to the peripheral vascular space, which is affected by Medtronic (MDT)/Covidien (COV) deal, Barclays said.

Franklin Resources (BEN) was upgraded at Goldman Sachs to buy from neutral. Better flow trends are being driven by emerging markets, and recent underperformance offers a cheap entry point, Goldman said.

GNC (GNC) was downgraded at J.P. Morgan to neutral. Company is seeing slower sales trends, and the CFO has left, J.P. Morgan said.

Gap (GPS - Get Report) was upgraded at Canaccord Genuity to buy from hold. Twelve-month price target is $51. Company can continue to expand margins, Canaccord Genuity said.

Medtronic was upgraded at Barclays to overweight from equal weight. Driven by potential benefits from acquisition of Covidien, Barclays said. Twelve-month price target is $73.

North European Oil Royalty Trust (NRT) was downgraded to hold at TheStreet Ratings.

Sunpower (SPWR) was downgraded at J.P. Morgan to neutral. Valuation call, as the stock is up 35% year to date, J.P. Morgan said. Twelve-month price target is $40.

Tyson Foods (TSN) upgraded at BMO Capital to outperform. Higher margins create opportunities for realized earnings potential in Hillshire and accelerated repaying of debts, BMO Capital said. Twelve-month price target is $43.

Walgreen (WAG) was upgraded at Barclays to overweight from equal weight. Driven by reducing expenses and optimizing capital structure, Barclays said. Twelve-month price target is $92.

Editor's note: To see analysts' stock comments and changes to price targets and earnings estimates, go to "Street Notes" which is available only to Real Money subscribers. To find out how to become a subscriber, please click here.

Follow TheStreet on Twitter and become a fan on Facebook.

Citigroup Looks Like a Smart Hedge as Interest Rates Remain Low

United Leads in China, but American and Delta Want Bigger Shares

This article was written by a staff member of TheStreet.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BCR $169.98 -0.96%
GPS $39.84 -0.30%
AAPL $131.08 -1.20%
FB $81.25 -0.81%
GOOG $552.88 -0.45%

Markets

DOW 17,976.13 -61.84 -0.34%
S&P 500 2,100.04 -8.88 -0.42%
NASDAQ 5,024.5320 -35.7140 -0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs